BioNTech SE (BNTX) Capital Expenditures (2018 - 2025)

BioNTech SE (BNTX) has 8 years of Capital Expenditures data on file, last reported at -$73.6 million in Q4 2025.

• In Q4 2025, Capital Expenditures fell 3.37% year-over-year to -$73.6 million; the TTM figure through Dec 2025 stood at -$197.6 million (up 36.26% YoY), while the FY2025 annual figure was -$197.8 million, up 35.38% from the prior year.
• Capital Expenditures declined to -$73.6 million in Q4 2025, from -$42.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at -$26.18 in Q1 2021 and bottomed at -$139.4 million in Q4 2022.
• A 5-year average of -$65.0 million and a median of -$67.4 million in 2024 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2021 — Capital Expenditures jumped 100.0% — and 2022, when it plunged 189090564.66%.
• Year by year, Capital Expenditures stood at -$45.1 million in 2021, then tumbled by 209.2% to -$139.4 million in 2022, then surged by 35.3% to -$90.2 million in 2023, then rose by 21.07% to -$71.2 million in 2024, then declined by 3.37% to -$73.6 million in 2025.
• The last three Capital Expenditures figures came in at -$73.6 million (Q4 2025), -$42.0 million (Q3 2025), and -$30.7 million (Q2 2025), per Business Quant data.

Peer Comparison